The pegfilgrastim biosimilar market is projected to register considerable growth in between 2020 and 2026. A Fact.MR study shows that coronavirus outbreak has deterred the opportunities in the market for a short term.
Dubai, UAE -- (SBWIRE) -- 11/24/2020 -- The pegfilgrastim biosimilar market is projected to register considerable growth in between 2020 and 2026. A Fact.MR study shows that coronavirus outbreak has deterred the opportunities in the market for a short term. Wide ranging field of applications in HIV/AIDS will also help in sustaining better growth for years to come.
"Improving healthcare facilities in developed economies like US presents key opportunities for the market players. Major participants have developed biosimilar to focus on cost-efficient cancer research and treatments," says the FACT.MR report.
Request for Sample Report @
https://www.factmr.com/connectus/sample?flag=S&rep_id=1494
Pegfilgrastim Biosimilar Market- Key Takeaways
Owing to extending cancer treatment measures in North America, this region remains the most lucrative amongst the others.
Strategic collaborations and partnerships will help in product innovation and improved demand to supply ratio.
Asia Pacific region will continue to remain the fastest growing market for pegfilgrastim biosimilars.
Regions are currently focussing on reimbursements policies and FDA approvals to gain a prominent market position.
Pegfilgrastim Biosimilar Market - Driving Factors
Pegfilgrastim is an essential drug for cancer treatments and is used in chemotherapy and radiotherapy neutropenia.
This medication stimulates the formation of white blood cells in the bone marrow to help the body fight infections.
Pegfilgrastim biosimilars treats patients with hematopietic subsyndrome of acute radiation syndrome and fuels adoption in pharmaceuticals.
Pegfilgrastim Biosimilar Market - Major Restraints
Higher costs limits its adoption in the Asia-Pacific region.
Limited information and awareness regarding the drug acts as a key factor hindering market growth prospects.
COVID-19 Impact on Pegfilgrastim Biosimilar Market
COVID-19 has surely affected clinical trials, which led to delays in the approval process. Delays caused due to pandemic crisis also leads to a backlog of approvals, and eventually delays the product launches. COVID-19 might also increase the number of deaths caused due cancer as the attention is towards the patients affected by the pandemic. Studies show that 28% of COVID-19 patients died with cancer which is two to three times the rate of people without cancer. Advanced healthcare facilities in USA and Europe can drive the market growth there but it's uncertain due to rising number of COVID cases.
Explore the global Pegfilgrastim Biosimilar market with 49 figures, 16 data tables, along with the table of contents of the report. You can also find detailed segmentation on @ https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market
Competitive Landscape
Market players are currently focussing on strategic collaborations and partnerships to strengthen their presence. Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG (Sandoz) are few of the major companies that come into play. Pfizer Inc, Green Cross Corp, Accord healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila are key participants too.
Ahmedabad based company, Intas Pharmaceutical ltd. Launched Azadine to benefit patients suffering from MDS and Acute Leukaemia.
Green Cross Corp collaborated with Aquavit Pharmaceuticals to develop and commercialize IBX-001 to personalize treatments and plasma-erivatives.
About the Report
This report offers a comprehensive market forecast of Pegfilgrastim biosimilars market. Global, regional and country-level representation of the top industry trends affecting the market is discussed in this FACT.MR study. The report offers insights on the market on the basis of channel (online, retail ), end user (biotechnology & pharmaceutical companies and contract research organizations) across regions (North America, Latin America, Europe, Asia Pacific, and MEA).
Explore FACT.MR's Comprehensive Coverage of Healthcare Landscape
Peptide Based Infection Therapeutics Market- Get an insight on the peptide-based infection therapeutics market through the report covering analysis for projection period (2017-2022).
Complementary Therapy Devices Market- FACT.MR's study regarding complementary therapy devices market presents trends, tech innovations, players, and strategies for 2018-2028.
Hemophilia Gene Therapy Market- Gain an analysis on the hemophilia gene therapy market through FACT.MR's report covering competitive analysis, regions, and segment analysis for 2018-2028.?
About Fact.MR
Fact.MR is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Fact.MR is headquartered in Dublin, and has offices in Dubai. Fact.MR's latest market research reports industry analysis help businesses navigate challenges and take critical decisions with confidence and clarity amidst breakneck competition.
Contact:
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
PR- https://www.factmr.com/media-release/1690/global-pegfilgrastim-biosimilar-market